Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status Prescription; Discontinued
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal tubular disorder20.05.03.004--Not Available
Respiratory distress22.02.01.0120.008747%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.002282%
Retinal degeneration06.09.03.002--Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.005831%
Retinal disorder06.08.03.0050.008747%Not Available
Retinopathy24.03.07.003; 06.10.02.0010.014578%
Scab23.03.03.004--Not Available
Seizure17.12.03.0010.008747%
Sepsis11.01.11.0030.004564%
Septic shock24.06.02.011; 11.01.11.0040.001521%Not Available
Serum ferritin increased13.11.01.0260.037903%Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.005831%
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.005831%Not Available
Splenomegaly01.09.02.0010.005831%Not Available
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.0070.008747%Not Available
Thrombocytopenia01.08.01.0020.005831%Not Available
Thrombocytosis01.08.02.0010.005831%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.005831%
Toxic encephalopathy17.13.01.004; 12.03.01.027--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.001521%
Unresponsive to stimuli17.02.05.0310.005831%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.0070.011662%
Visual acuity reduced17.17.01.011; 06.02.03.0010.034987%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages